What is new in the pathology of pancreatic neuroendocrine tumors?

Komminoth, P; Perren, Aurel (2015). What is new in the pathology of pancreatic neuroendocrine tumors? Pathologe, 36(3), pp. 220-228. Springer-Medizin-Verlag 10.1007/s00292-015-0023-1

[img] Text
art%3A10.1007%2Fs00292-015-0023-1.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

The diagnostics of pancreatic neuroendocrine tumors (PanNEN) have changed in recent years especially concerning the World Health Organization (WHO) classification, TNM staging and grading. Furthermore, some new prognostic and predictive immunohistochemical markers have been introduced. Most progress, however, has been made in the molecular pathogenesis of these neoplasms. Using next generation sequencing techniques, the mammalian target of rapamycin (mTOR) pathway, hypoxia and epigenetic changes were identified as key players in tumorigenesis. In this article the most important developments of morphological as well as immunohistochemical diagnostics together with the molecular background of PanNEN are summarized.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Perren, Aurel

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0172-8113

Publisher:

Springer-Medizin-Verlag

Language:

German

Submitter:

Doris Haefelin

Date Deposited:

14 Jul 2015 11:12

Last Modified:

04 Nov 2016 10:31

Publisher DOI:

10.1007/s00292-015-0023-1

PubMed ID:

25941099

BORIS DOI:

10.7892/boris.70230

URI:

https://boris.unibe.ch/id/eprint/70230

Actions (login required)

Edit item Edit item
Provide Feedback